Is There a Role for α-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-200363100-00002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathophysiology of Diabetes

  2012cited by this paper
• Preventing Long Term Complications

  2012cited by this paper
• Orlistat

  2012cited by this paper
• Drug Therapy of Postprandial Hyperglycaemia

  2012cited by this paper
• Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

  2012cited by this paper
• α‐GLUCOSIDASE INHIBITION IN OBESITY

  2009cited by this paper
• Ischaemic heart disease, stroke and total mortality in women--results from a prospective population study in Gothenburg, Sweden.

  2009cited by this paper
• The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.

  2009cited by this paper
• Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes

  2004cited by this paper
• Therapy of Type 2 Diabetes Mellitus

  2004cited by this paper
• Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

  2004cited by this paper
• Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients

  2003cited by this paper
• The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century.

  2003cited by this paper
• PATHOPHYSIOLOGY OF TYPE 2 DIABETES

  2003cited by this paper
• Evaluation of Potential

  2003cited by this paper
• Approches pharmacologiques de prévention du diabète de type 2

  2002cited by this paper
• Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1

  2002cited by this paper
• Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.

  2002cited by this paper
• Acarbose for type 2 diabetes prevention.

  2002cited by this paper
• Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.

  2002cited by this paper
• Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.

  2002cited by this paper
• The prevention or delay of type 2 diabetes.

  2002cited by this paper
• Minor long‐term changes in weight have beneficial effects on insulin sensitivity and β‐cell function in obese subjects

  2002cited by this paper
• Accurate Assessment of β-Cell Function: The Hyperbolic Correction

  2002cited by this paper
• Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.

  2002cited by this paper
• Acarbose for type 2 diabetes prevention.

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

  2002cited by this paper
• Diabetes Therapeutics News

  2002cited by this paper
• Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects.

  2002cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

  2001cited by this paper
• The Management of Obesity and Related Disorders

  2001cited by this paper
• Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed

  2001cited by this paper
• The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

  2001cited by this paper
• Ramipril and the development of diabetes.

  2001cited by this paper
• Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.

  2001cited by this paper
• Predictors of persistence of use of the novel antidiabetic agent acarbose.

  2001cited by this paper
• Diet and risk of Type II diabetes: the role of types of fat and carbohydrate

  2001cited by this paper
• Oral therapies for diabetic hyperglycemia.

  2001cited by this paper
• Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.

  2001cited by this paper
• Possible Prevention of Type 2 Diabetes with Acarbose or Metformin

  2000cited by this paper
• Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight

  2000cited by this paper
• Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus

  2000cited by this paper
• Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

  2000cited by this paper
• Miglitol: Assessment of its Role in the Treatment of Patients with Diabetes Mellitus

  2000cited by this paper
• Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

  2000cited by this paper
• Antidiabetic Drugs Present and Future

  2000cited by this paper
• Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

  2000cited by this paper
• Management of the Obese Diabetic Patient

  2000cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• The impact of pharmacotherapy on weight management in type 2 diabetes

  1999cited by this paper
• Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study.

  1999cited by this paper
• A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

  1999cited by this paper
• Pharmacologic Therapy for Type 2 Diabetes Mellitus

  1999cited by this paper
• Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?

  1999cited by this paper
• Obesity and diabetes.

  1999cited by this paper
• The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus A model of medicine-based evidence

  1999cited by this paper
• Marked weight loss in a type 2 diabetic patient treated with acarbose.

  1999cited by this paper
• Effects of the α‐glucosidase inhibitor acarbose on the development of long‐term complications in diabetic animals: pathophysiological and therapeutic implications

  1999cited by this paper
• Diabetes in the New Millennium

  1999cited by this paper
• European Comparative Study of 2 Alpha-Glucosidase Inhibitors, Miglitol and Acarbose

  1999cited by this paper
• Prolonged and enhanced secretion of glucagon‐like peptide 1 (7‐36 amide) after oral sucrose due to α‐glucosidase inhibition (acarbose) in Type 2 diabetic patients

  1998cited by this paper
• Assessing the potential for α-glucosidase inhibitors in prediabetic states

  1998cited by this paper
• European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

  1998cited by this paper
• Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.

  1998cited by this paper
• An Asian Multicenter Clinical Trial to Assess the Efficacy and Tolerability of Acarbose Compared With Placebo in Type 2 Diabetic Patients Previously Treated With Diet

  1998cited by this paper
• The postprandial state and risk of cardiovascular disease

  1998cited by this paper
• Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus

  1998cited by this paper
• Effects of Voglibose on Glycemic Excursions, Insulin Secretion, and Insulin Sensitivity in Non-lnsulin-ireated NIDDM Patients

  1998cited by this paper
• Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus.

  1998cited by this paper
• Oral Antidiabetic Agents

  1998cited by this paper
• Place de l'acarbose dans le traitement du diabete sucre.

  1998cited by this paper
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

  1998cited by this paper
• Potential of α-Glucosidase Inhibitors in Elderly Patients with Diabetes Mellitus and Impaired Glucose Tolerance

  1998cited by this paper
• The STOP-NIDDM Trial: An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data

  1998cited by this paper
• Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects.

  1998cited by this paper
• The benefits of modest weight loss in type II diabetes.

  1997cited by this paper
• Hyperleptinaemia: the Missing Link in the Metabolic Syndrome?

  1997cited by this paper
• Predictors of Progression From Impaired Glucose Tolerance to NIDDM: An Analysis of Six Prospective Studies

  1997cited by this paper
• α-Glucosidase inhibitors in the treatment of diabetes

  1997cited by this paper
• Glibenclamide, but Not Acarbose, Increases Leptin Concentrations Parallel to Changes in Insulin in Subjects With NIDDM

  1997cited by this paper
• Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

  1997cited by this paper
• Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.

  1997cited by this paper
• Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s

  1997cited by this paper
• Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.

  1997cited by this paper
• The Clinical Implications of Impaired Glucose Tolerance

  1996cited by this paper
• Appraisal of effectiveness and potential therapeutic benefit of acarbose: A non-consensus conference

  1996cited by this paper
• Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.

  1996cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Acarbose

  1996cited by this paper
• The Effect of Acarbose on Insulin Sensitivity in Subjects With Impaired Glucose Tolerance

  1996cited by this paper
• Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

  1996cited by this paper
• Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects.

  1996cited by this paper
• Does Suppression of Postprandial Blood Glucose Excursions by the α-Glucosidase Inhibitor Miglitol Improve Insulin Sensitivity in Diet-Treated Type II Diabetic Patients?

  1996cited by this paper
• Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.

  1995cited by this paper
• Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Improving the action of insulin.

  1995cited by this paper
• Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose).

  1995cited by this paper
• Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison study

  1995cited by this paper

• Synthesis and profiling (in vitro and in silico) of the 6-methoxy/hydroxy substituted 7-acetyl-2-aryl-5-bromobenzofurans for antihyperglycemic, cytotoxic and antioxidant properties.

  2025cites this paper
• Design, Synthesis, and Bioactivity Evaluation of Novel Vanillic Acid Derivatives Containing an 1,2,4-Triazole Thioether Moiety

  2025cites this paper
• Review of plants as a promising source of bioactive peptides for the treatment of diabetes

  2025cites this paper
• Multi-target mechanisms of diabetic inhibitory peptides derived from longan seed protein hydrolysate

  2025cites this paper
• Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial

  2024cites this paper
• From millets to medicine: ADMET insights into diabetes management with P. sumatrense compounds

  2024cites this paper
• Employing Machine Learning Models to Predict Potential α-Glucosidase Inhibitory Plant Secondary Metabolites Targeting Type-2 Diabetes and Their In Vitro Validation

  2024cites this paper
• The Anti-Diabetic Effects of Medicinal Plants Belonging to the Liliaceae Family: Potential Alpha Glucosidase Inhibitors

  2024cites this paper
• Formulation and Evaluation of Bilayer Matrix Tablet of Vildagliptin and Acarbose

  2024cites this paper
• In vitro antioxidant and alpha-glucosidase inhibitory activities of coriander (Coriandrum sativum L.) root extracts

  2024cites this paper
• Clinical applications and mechanism insights of natural flavonoids against type 2 diabetes mellitus

  2024cites this paper
• Application of two-dimensional reversed phase countercurrent chromatography × high-performance liquid chromatography to bioactivity-guided screening and isolation of α-glucosidase inhibitors from Rheum palmatum L.

  2024cites this paper
• Diphenolic boldine, an aporphine alkaloid: inhibitory effect evaluation on α-glucosidase by molecular dynamics integrating enzyme kinetics

  2024cites this paper
• Antioxidant, antidiabetic, neuroprotective, and phytochemical evaluation of Chenopodium ambrosioides ethanol extract

  2024cites this paper
• Bile acids: Can the position of hydroxyl substitution influence antidiabetic potency?

  2024cites this paper
• Enzyme (α-Glucosidase, α-Amylase, PTP1B & VEGFR-2) Inhibition and Cytotoxicity of Fluorinated Benzenesulfonic Ester Derivatives of the 5-Substituted 2-Hydroxy-3-nitroacetophenones

  2024cites this paper
• Exploring the 3,5-Dibromo-4,6-dimethoxychalcones and Their Flavone Derivatives as Dual α-Glucosidase and α-Amylase Inhibitors with Antioxidant and Anticancer Potential

  2024cites this paper
• Targeting α-amylase enzyme through multi-fold structure-based virtual screening and molecular dynamic simulation

  2023cites this paper
• Bioprospecting of Sea Anemones (Cnidaria, Anthozoa, Actiniaria) for β-Defensin-like α-Amylase Inhibitors

  2023cites this paper
• New anti-α-Glucosidase and Antioxidant Ingredients from Winery Byproducts: Contribution of Alkyl Gallates

  2023cites this paper
• Activity, structural features and in silico digestion of antidiabetic peptides

  2023cites this paper
• Drug Repurposing of FDA Compounds against α-Glucosidase for the Treatment of Type 2 Diabetes: Insights from Molecular Docking and Molecular Dynamics Simulations

  2023cites this paper
• Alpha-glucosidase inhibition and antioxidant activity of Ensete superbum (Roxb.) Cheesman seeds: GC-MS-based profiling of the active metabolites and molecular docking study

  2022cites this paper
• " Type 2 Diabetes: Contemporary Challenges " Clinical Pharmacology of Antidiabetic Drugs: what can be expected of their use?

  2022cites this paper
• Synthesis, in-vitro α-glucosidase inhibition and molecular docking studies of 1,3,4-thiadiazole-5,6-diphenyl-1,2,4-triazine hybrids: Potential leads in the search of new antidiabetic drugs

  2022cites this paper
• Metabolite profiling of Nymphaea rubra (Burm. f.) flower extracts using cyclic ion mobility-mass spectrometry and their associated biological activities.

  2022cites this paper
• Reproductive and Developmental Toxicology Studies of Iminosugar UV-4.

  2022cites this paper
• Dandelion (Taraxacum officinale L.) as a Source of Biologically Active Compounds Supporting the Therapy of Co-Existing Diseases in Metabolic Syndrome

  2022cites this paper
• Synthesis of N-Substituted Iminosugar C-Glycosides and Evaluation as Promising α-Glucosidase Inhibitors

  2022influential citation
• Synthesis of Novel 2,3-Dihydro-1,5-Benzothiazepines as α-Glucosidase Inhibitors: In Vitro, In Vivo, Kinetic, SAR, Molecular Docking, and QSAR Studies

  2022cites this paper
• Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects

  2022cites this paper
• Flavone-1,2,3-triazole derivatives as potential α-glucosidase inhibitors: Synthesis, enzyme inhibition, kinetic analysis and molecular docking study.

  2022cites this paper
• Gaining deeper insights into 2,5-disubstituted furan derivatives as potent α-glucosidase inhibitors and discovery of putative targets associated with diabetes diseases using an integrative computational approach

  2022cites this paper
• Inhibition of alpha-glucosidase enzyme and antioxidant activity of the metabolites purified from an endophytic fungus of Simarouba glauca DC

  2022cites this paper
• Cyanoacetohydrazide linked to 1,2,3-triazole derivatives: a new class of α-glucosidase inhibitors

  2022cites this paper
• PELARGONIUM GRAVEOLENS (ROSE GERANIUM) – THERAPEUTIC AGENT FOR ANTIBACTERIAL, ANTIOXIDANT, ANTIFUNGAL AND DIABETICS,ANTI-INFLAMMATORY

  2022cites this paper
• A Treatment to Cure Diabetes Using Plant-Based Drug Discovery

  2022cites this paper
• Design, Synthesis, In‐Vivo Anti‐Diabetic Activity, In‐Vitro α‐Glucosidase Inhibitory Activity and Molecular Docking Studies of Some Quinazolinone Derivatives

  2022cites this paper
• Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent

  2022cites this paper
• In vitro α-glucosidase inhibition by Brazilian medicinal plant extracts characterised by ultra-high performance liquid chromatography coupled to mass spectrometry

  2022cites this paper
• Mitochondria as an important target of metformin: the mechanism of action, toxic and side effects, and new therapeutic applications.

  2022cites this paper
• Design, synthesis, biological evaluations and in silico studies of sulfonate ester derivatives of 2-(2-benzylidenehydrazono)thiazolidin-4-one as potential α-glucosidase inhibitors

  2022cites this paper
• Aroma Profile and α-Glucosidase Inhibitory Activity of Essential Oil of Mentha spicata Leaves

  2021cites this paper
• Omeprazole inhibits α-glucosidase activity and the formation of nonenzymatic glycation products: Activity and mechanism.

  2021cites this paper
• Drug Resistance in Diabetes

  2021cites this paper
• Chemical Composition, α-Glucosidase Inhibitory and Anticancer Activity of Essential Oil of Thymus vulgaris Leaves

  2021cites this paper
• Rice Compounds with Impact on Diabetes Control

  2021cites this paper
• Chemical Characterization and Antidiabetic Activity of Essential Oils from Pelargonium graveolens Leaves

  2021cites this paper
• Chemical Characterization and α-Glucosidase Inhibitory Activity of Essential Oil of Lavandula angustifolia Flowers

  2021cites this paper
• In Vitro Pharmacological Screening of Antioxidant, Photoprotective, Cholinesterase, and α-Glucosidase Inhibitory Activities of Algerian Crataegus oxyacantha Fruits and Leaves Extracts

  2021cites this paper
• Anti-insulin resistance effect of constituents from Senna siamea on zebrafish model, its molecular docking, and structure–activity relationships

  2021cites this paper
• Synthesis, in-vitro evaluation, molecular docking, and kinetic studies of pyridazine-triazole hybrid system as novel α-glucosidase inhibitors.

  2021cites this paper
• Network pharmacology combined with metabolomics to study the mechanism of Shenyan Kangfu Tablets in the treatment of diabetic nephropathy.

  2021cites this paper
• Molecular prospect of type-2 diabetes: Nanotechnology based diagnostics and therapeutic intervention

  2020cites this paper
• EMERGENCE OF BENZOTHIAZOLE AND ITS DERIVATIVES AS A POTENTIAL ANTIDIABETIC PROBE

  2020cites this paper
• Complete Biosynthesis of the Anti-Diabetic Plant Metabolite Montbretin A1[OPEN]

  2020cites this paper
• Anti-Diabetic Potential of Anti-Oxidant Compounds "Riboflavin, Flavin Mononucleotide and Flavin Adenine Dinucleotide" with High Therapeutic Potency through Inhibition of α-Amylase and α-Glucosidase Enzymes at Sub-Micromolar Concentrations

  2020cites this paper
• Evidence based study of Hypoglycemic Potential of Bitter Melon Peptide

  2020cites this paper
• Isorhapontigenin Improves Diabetes in Mice via Regulating the Activity and Stability of PPARγ in Adipocytes.

  2020cites this paper
• Chemical Composition and In vitro Antidiabetic Effects of Olea europaea Linn. (Olive)

  2020cites this paper
• Hypoglycaemic effect of all-trans astaxanthin through inhibiting α-glucosidase

  2020cites this paper
• Standardized Extract from Enicostemma littorale Ameliorates Post-prandial Hyperglycaemia in Normal and Diabetic Rats

  2020cites this paper
• Amelioration of Diabetes mellitus by modulation of GLP-1 via targeting alpha-glucosidase using Acacia tortilis polysaccharide in Streptozotocin-Nicotinamide induced diabetes in rats

  2020cites this paper
• Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

  2019influential citation
• The first target specific, highly diastereoselective synthesis, design and characterization of pyranoquinolinyl acrylic acid diastereomers as potential α-glucosidase inhibitors.

  2019cites this paper
• Enzyme immobilized on polyamidoamine-coated magnetic microspheres for α-glucosidase inhibitors screening from Radix Paeoniae Rubra extracts accompanied with molecular modeling.

  2019cites this paper
• Proteins with Evolutionarily Hypervariable Domains are Associated with Immune Response and Better Survival of Basal-like Breast Cancer Patients

  2019cites this paper
• Maltase-glucoamylase inhibition potency and cytotoxicity of pyrimidine-fused compounds: An in silico and in vitro approach

  2019cites this paper
• Therapeutic Evaluation of Herbs With Enzyme Inhibition Studies

  2019cites this paper
• Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes

  2019cites this paper
• Biosynthesis of the anti‐diabetic metabolite montbretin A: glucosylation of the central intermediate mini‐MbA

  2019cites this paper
• Coumarin tethered cyclic imides as efficacious glucose uptake agents and investigation of hit candidate to probe its binding mechanism with human serum albumin.

  2019cites this paper
• MiR-26a and miR-26b downregulate the expression of sucrase-isomaltase enzyme: A new chapter in diabetes treatment.

  2019cites this paper
• Magnificamide, a β-Defensin-Like Peptide from the Mucus of the Sea Anemone Heteractis magnifica, Is a Strong Inhibitor of Mammalian α-Amylases

  2019cites this paper
• Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.

  2019cites this paper
• Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

  2019cites this paper
• Essential Oil Composition and Antidiabetic, Anticancer Activity of Rosmarinus officinalis L. Leaves from Erbil (Iraq)

  2019cites this paper
• Synthesis, molecular modeling and evaluation of α-glucosidase inhibition activity of 3,4-dihydroxy piperidines.

  2018cites this paper
• Synthesis, in vitro α-glucosidase inhibitory potential and molecular docking study of thiadiazole analogs.

  2018cites this paper
• Starch Digestion and Applications of Slowly Available Starch

  2018cites this paper
• Potential of rooibos, its major C-glucosyl flavonoids, and Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid in prevention of metabolic syndrome

  2018cites this paper
• Phase 1 Study of the Pharmacology of BTI320 Before High‐Glycemic Meals

  2018cites this paper
• Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

  2018cites this paper
• Discovery of UDP-Glycosyltransferases and BAHD-Acyltransferases Involved in the Biosynthesis of the Antidiabetic Plant Metabolite Montbretin A[OPEN]

  2018cites this paper
• Voglibose: An Important Drug for Type 2 Diabetes

  2017cites this paper
• DEVELOPMENT AND VALIDATION OF LC-MS/MS METHOD FOR THE SIMULTANEOUS DETERMINATION OF PIOGLITAZONE AND VOGLIBOSE IN HUMAN PLASMA

  2017cites this paper
• Synthesis of novel flavonoid alkaloids as α-glucosidase inhibitors.

  2017cites this paper
• Agrimoniin, an Active Ellagitannin from Comarum palustre Herb with Anti-α-Glucosidase and Antidiabetic Potential in Streptozotocin-Induced Diabetic Rats

  2017cites this paper
• Synthesis, molecular structure, spectral analysis, and biological activity of new malonamide derivatives as α-glucosidase inhibitors

  2017cites this paper
• Coumarins as potential antidiabetic agents

  2017cites this paper
• Rapid Discovery of Potent and Selective Glycosidase-Inhibiting De Novo Peptides.

  2017cites this paper
• α-Glucosidase inhibitory effect of resveratrol and piceatannol.

  2017cites this paper
• Towards Tuneable Retaining Glycosidase‐Inhibiting Peptides by Mimicry of a Plant Flavonol Warhead

  2017cites this paper
• Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).

  2016cites this paper
• Diabetes and Health Care: An Overview

  2016cites this paper
• Hyperglycemic and Hypoglycemic Drugs

  2016cites this paper
• Comparative Analysis of the Bonding Modes between Two Antidiabetic Drugs with beta-Glucosidases from Different Species

  2016cites this paper
• Fermentation of purple Jerusalem artichoke extract to improve the α-glucosidase inhibitory effect in vitro and ameliorate blood glucose in db/db mice

  2016cites this paper
• Synthesis of novel flavone hydrazones: in-vitro evaluation of α-glucosidase inhibition, QSAR analysis and docking studies.

  2015cites this paper
• Investigation of antihyperglycaemic activity of banana (Musa sp. var. Nanjangud rasa bale) pseudostem in normal and diabetic rats.

  2015cites this paper